Preparation of compounded products in pharmacies and compounding-magistral pharmacy, personalized medicine in Türkiye and Spain

Year 2024, Volume: 28 Issue: 6, 2181 - 2201, 28.06.2025

Erol Eli Simsolo Ahmet Nezihi Pekcan Zeki Erdinç Ülker Hilmi Bakır , Ayşe Nilhan Atsü , İsmail Aslan

Abstract

The pharmacist is the only individual authorised to prepare medicines as a result of the training they have received. The pharmacy profession is one of the few that will not accept mistakes in terms of human life and health. Even the smallest mistake can lead to irreversible consequences such as non-recovery, disability and death. In the event of such a situation, every sensitive pharmacist will undoubtedly face a great deal of conscientious responsibility. In order to avoid such a situation, it is necessary to be aware of the developments in the profession and to exercise caution when providing services. It is also important to avoid leaving work to others and to strive to avoid making any mistakes. Personalised medicines prepared by a pharmacist in a pharmacy laboratory according to a doctor's prescription, packaged and labelled, and presented to the patient are known as magistral products. These are formulations that are prescribed and prepared individually, with the doses of the active substance determined by the physician in terms of volume or weight according to the degree of the disease present in the patient. In the context of personalised therapies globally, the importance of compounding products is increasing daily, and the rules and regulations governing the preparation of compounding products vary from country to country.

Keywords

Compounded Products , Compounding Pharmacy , Pharmacy , Magistral , i.v. Nutrition , Hormon Replacement Therapy , Personalized Medicine , Pharmacies in Türkiye , Spain

References

• [1] Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012; 11(4): 267–268. https://dx.doi.org/10.1038/nrd3654
• [2] Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013; 69(4): 1009–1024. https://dx.doi.org/10.1007/s00228-012-1423-2
• [3] Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012; 17(13-14): 660–664. https://dx.doi.org/10.1016/j.drudis.2012.02.005
• [4] Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: Development trends and strategies. J Pharm Bioallied Sci. 2010; 2(4): 290–299. https://dx.doi.org/10.4103/0975-7406.72128
• [5] Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical compounding: A history, regulatory overview, and systematic review of compounding errors. J Med Toxicol. 2021; 17(2): 197–217. https://dx.doi.org/10.1007/s13181-020-00814-3
• [6] Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs in R&D. 2013; 13(1): 1–8. https://dx.doi.org/10.1007/s40268-013-0005-9
• [7] Deng Y, Lin AC, Hingl J, Huang G, Altaye M, Maynard H, Mayhaus D, Penm J. Risk factors for i.v. compounding errors when using an automated workflow management system. Am J Health Syst Pharm. 2016; 73(12): 887–893. https://dx.doi.org/10.2146/ajhp150278
• [8] Mullarkey T. Pharmacy compounding of high-risk level products and patient safety. Am J Health Syst Pharm. 2009; 66(5): 4–13. https://dx.doi.org/10.2146/ajhp0108b
• [9] Dennis VC, Owora AH, Kirkpatrick AE. Comparison of aseptic compounding errors before and after modified laboratory and ıntroductory pharmacy practice experiences. Am J Pharm Educ. 2015; 79(10): 158. https://dx.doi.org/10.5688/ajpe7910158
• [10] Hamoda H. Availability of menopausal hormone therapy products worldwide. Maturitas. 2020; 141: 87–88. https://dx.doi.org/10.1016/j.maturitas.2020.02.002
• [11] Kırıcı P, Tanrıverdi ES. Effects of different progesterone doses on the concentrations of proinflammatory and anti inflammatory cytokines in pregnant women with threatened abortion. Cureus. 2021; 13(11): e19333. https://dx.doi.org/10.7759/cureus.19333
• [12] Behre HM, Tammela TLJ, Arver S, Tolrá JR, Bonifacio V, Lamche M, Gooren LJ. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. https://dx.doi.org/10.3109/13685538.2012.699562
• [13] Palan, AP, Baksu A, Çelebi Ş, Gültekin T, Ince Z, Göker N. Comparison of the effect of transdermal and intranasal estrogen treatments on serum hormone and lipid levels and mammographic densities in surgical menopause. Bull Sisli Etfal Hosp. 2009; 43(2): 65-71.
• [14] Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: A review. Menopause. 2004; 11(3): 356-367. https://dx.doi:10.1097/01.GME.0000094356.92081.EF
• [15] Loder EW, Buse DC, Golub, JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. Am J Obstet Gynecol, 2005; 193(3): 636-649. https://dx.doi.org/10.1016/j.ajog.2004.12.089
• [16] Aslan İ, Aytekin AF. Production and characterization of newly developed alcohol-free topical liposome-gel transdermal drug delivery systems containing estradiol (E2)/ estriol (E3) for post-menopausal women. J Res Pharm. 2023; 27(5): 2190-2198. http://dx.doi.org/10.29228/jrp.499
• [17] Aslan İ, Kurt AA. Characterization and optimization of phytosome formulation containing alcohol-free umckalin from Pelargonium sidoides. Curr Perspect Med Aroma Plant. 2020; 3(1): 49-53. https://dx.doi.org/10.38093/cupmap.737878
• [18] Aslan İ, Kurt AA. In-vitro comparison release study of novel liposome and conventional formulation containing Rosmarinus officinalis extract. Curr Perspect Med Aroma Plant. 2021; 4(1): 13-21. https://dx.doi.org/10.38093/cupmap.848115
• [19] Duman G, Aslan İ, Özer AY, İnanç İ, Taralp A. Liposome, gel and lipogelosome formulations containing sodium hyaluronate. J Liposome Res. 2014; 24(4): 259–269. https://dx.doi.org/10.3109/08982104.2014.907305
• [20] Akın F, Aslan N. COVID-19 pandemisinde okul öncesi dönemdeki öğrencilerin uzaktan eğitimi: Bir eylem araştırması. Alanyazın. 2021; 2(1): 8-17.
• [21] Ayseli YI, Aytekin N, Buyukkayhan D, Aslan I, Ayseli MT. Food policy, nutrition and nutraceuticals in the prevention and management of COVID-19: Advice for healthcare professionals. Trends Food Sci Technol. 2020; 105: 186–199. https://dx.doi.org/10.1016/j.tifs.2020.09.001
• [22] Karakose T, Demirkol M, Aslan N, Köse H, Yirci R. A conversation with ChatGPT about the impact of the COVID-19 pandemic on education: Comparative review based on human–AI collaboration. Ed Process Int J. 2023; 12(3): 7-25. https://dx.doi.org/10.22521/edupij.2023.123.1
• [23] Aslan I, Tarhan Celebi L, Kayhan H, Kizilay E, Gulbahar MY, Kurt H, Cakici B. Probiotic formulations containing fixed and essential oils ameliorates SIBO-induced gut dysbiosis in rats. Pharmaceuticals. 2023; 16(7):1041. https://dx.doi.org/10.3390/ph16071041
• [24] Cuevas-González PF, Liceaga AM, Aguilar-Toalá JE. Postbiotics and paraprobiotics: From concepts to applications. Food Res Int. 2020; 136: 109502. https://dx.doi.org/10.1016/j.foodres.2020.109502
• [25] Aslan İ, Tarhan Çelebi L. Postbiotics cosmetic formulation: In vitro efficacy studies on a microbiome friendly antiperspirant. J Res Pharm. 2023; 27(5): 2095-2105. http://dx.doi.org/10.29228/jrp.488
• [26] Kurt AA, Aslan I, Duman G. Next-Generation natural baby barrier cream formulations: Physicochemical analysis and safety assessment. J Cosmet Sci. 2021; 72(2): 173-188.
• [27] Atsü AN, Karakayalı G, Allı N, Güngör E. Alopesi areatalı hastalarda hemoglobin, hematokrit ve serum ferritin düzeyleri. Turkiye Klinikleri J Dermatol. 1998; 8(3): 121-124.
• [28] Atsü AN, Caf N, Türkoğlu Z, Kutlubay Z. Nodular alopecic lesions. In: Waśkiel-Burnat A, Sadoughifar R, Lotti TM, Rudnicka L. (eds) Clinical Cases in Scalp Disorders. Clinical Cases in Dermatology. Springer, Cham, 2022, pp 245 249 https://dx.doi.org/10.1007/978-3-030-93426-2_56
• [29] Atsü AN, Oruc Adalı G, Caf N, Türkoglu Z. Evaluation of demographic and clinical data of herpes zoster patients admitted to tertiary referral dermatology clinic during COVID-19 pandemic. Dicle Tıp Derg. 2022; 49(1): 111-118. https://dx.doi.org/10.5798/dicletip.1086294
• [30] Atsü AN, Caf N, Türkoğlu Z, Özkoca D, Yıldırım O, Ergin Ç. Comparison of malassezia colonization of 'Maskne' patients with seborrheic dermatitis cases and healthy individuals. Indian J Dermatol. 2022; 67(5): 483-487. https://dx.doi.org/10.4103/ijd.ijd_237_22
• [31] Caf N, Özkök Akbulut T, Can MM, Sarı M, Atsü AN, Türkoğlu, Z. Evaluation of subclinical atherosclerosis in rosacea patients by flow‐mediated dilatation method. J Cosmet Dermatol. 2023; 22(3): 1001-1010. https://dx.doi.org/10.1111/jocd.15492
• [32] Atsü AN, Caf N, Erdoğan B, Türkoğlu Z. Evaluation of the knowledge of sun damage, solar protection and skin cancers among university students and their parents. Acibadem Univ Saglik Bilim Derg. 2022; 13 (1): 21–29. https://dx.doi.org/10.31067/acusaglik.1028522
• [33] Bilgiç T, Caf N, Atsü AN. Partial effect of resveratrol on wound healing: study on wistar albino rats. Eurasian J Med Investig. 2021; 5(4): 460-468. https://dx.doi.org/10.14744/ejmi.2021.97868
• [34] Günal MY, Ayla Ş, Bedri N, Beker MÇ, Çağlayan AB, Aslan İ, Özdemir EM, Yeşilada E, Kılıç Ü. The effects of topical liposomal resveratrol on incisional and excisional wound healing process. TURKDERM- Turk Arch Dermatol Venereol. 2019; 53(4): 128-134. https://dx.doi.org/10.4274/turkderm.galenos.2019.82612
• [35] Gunal MY, Ayla S, Caglayan B, Beker MC, Bedri N, Aslan I, Ozdemir EM, Kilic E, Yesilada E. Can Carpobrotus edulis, heal incisional and excisional wounds on the skin? Bratisl Lek Listy/Bratisl Med J. 2021; 122(12): 912–917. https://dx.doi.org/10.4149/BLL_2021_147
• [36] Yazici M, Duman G, Aslan I, Durucan A, Sahin F. The antifungal activity of liposomal ointment formulation of essential oil of Satureja hortensis. Curr Opin Biotechnol. 2011; 22: 108-108. https://dx.doi.org/10.1016/j.copbio.2011.05.345
• [37] Castro-Balado A, González-Barcia M. Regulación de la innovación en formulación magistral oftálmica. Farm Hosp. 2020; 44(4): 123-124. https://dx.doi.org/10.7399/fh.11452
• [38] Gastelurrutia MA, Faus MJ, Fernández-Llimós F. Providing patient care in community pharmacies in Spain. Ann Pharmacother. 2005; 39(12): 2105-2110. https://dx.doi.org/10.1345/aph.1G121.
• [39] Ramírez CC, Palomo MG, García-Palop B, Poy MJ. Formulación magistral y excipientes en pediatría. El Farmacéutico Hospitales, 2018; 213: 22-28.
• [40] Uriel M, Marro D, Gómez Rincón C. An adequate pharmaceutical quality system for personalized preparation. Pharmaceutics. 2023; 15(3): 800. https://dx.doi.org/10.3390/pharmaceutics15030800
• [41] Documento de instrucciones de la Agencia Española de Medicamentos y Productos Sanitarios para la realización de ensayos clínicos en España. https://www.aemps.gob.es/investigacionClinica/medicamentos/docs/Instrucciones realizacion-ensayos-clinicos-EN.pdf?x19374 (accessed November 27, 2023).
• [42] Pharmaceutical Preparations European Pharmacopoeia, seventh ed. Supplement S7.7, Worldwide Book Service Wickford, UK, 2013.
• [43] T.C. Bilim, Sanayi ve Teknoloji Bakanlığı, Sanayi Genel Müdürlüğü, Türkiye İlaç Sektörü Strateji Belgesi ve Eylem Planı 2015-2018. https://www.resmigazete.gov.tr/eskiler/2015/08/20150809-16-1.pdf (accessed July 09, 2024).
• [44] Eczacılar ve Eczaneler Hakkında Yönetmelik. https://www.resmigazete.gov.tr/eskiler/2014/04/20140412-14.htm (accessed April 12, 2024).
• [45] İspençiyari ve Tıbbi Müstahzarlar Kanunu. https://www.mevzuat.gov.tr/MevzuatMetin/1.3.1262.pdf (accessed April 20, 2024).
• [46] Eczacılar ve Eczaneler Hakkında Kanun Üçüncü Bölüm. https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=6197&MevzuatTur=1&MevzuatTertip=3 (accessed March 01, 2024).
• [47] Eczacılar Birliği Kanunu. https://www.saglik.gov.tr/TR-10394/eczacilar-birligi-kanunu.html (accessed June 12, 2024).
• [48] Eczacılar ve Eczaneler Hakkında Kanun Beşinci Bölüm. https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=19569&MevzuatTur=7&MevzuatTertip=5 (accessed March 01, 2024).
• [49] Türk Ceza Kanunu. https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=5237&MevzuatTur=1&MevzuatTertip=5 (accessed June 02, 2024).
• [50] Türk Eczacıları Deontoloji Tüzüğü. https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=610314&MevzuatTur=2&MevzuatTertip=5 (accessed March 05, 2024).
• [51] Instruction document of the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain. https://www.aemps.gob.es/investigacionClinica/medicamentos/docs/Instrucciones-realizacion-ensayos clinicos-v16-EN.pdf?x55286 (accessed June 06, 2022).